Antitumor agent-61

• UNSPSC Description:

  Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC50s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways[1].

• Target Antigen:

  Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/antitumor-agent-61.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1CCC(CC1)N2CCCCC2)OC3=CC4=C(CC)C5=C(C6=CC7=C(COC(C7(CC)OC(CCCC8=CC=C(NC(P(OCC)(OCC)=O)C9=CC=C(C=C9)F)C=C8)=O)=O)C(N6C5)=O)N=C4C=C3

• Molecular Weight:

  992.08

• References & Citations:

  [1]Xiaochao Huang, et al. Synthesis, mechanisms of action, and toxicity of novel aminophosphonates derivatives conjugated irinotecan in vitro and in vivo as potent antitumor agents. Eur J Med Chem. 2020 Mar 1;189:112067.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  9007-83-4